Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,268Revenue $M375Net Margin (%)15.3Z-Score5.3
Enterprise Value $M1,282EPS $1.8Operating Margin %14.0F-Score7
P/E(ttm))22.6Cash Flow Per Share $1.3Pre-tax Margin (%)12.2Higher ROA y-yY
Price/Book5.110-y EBITDA Growth Rate %4.4Quick Ratio1.4Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %11.0Current Ratio2.3Lower Leverage y-yY
Price/Cash Flow8.9y-y EBITDA Growth Rate %2.6ROA % (ttm)12.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)25.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M31.1ROI % (ttm)25.6Gross Margin Increase y-yY

Gurus Latest Trades with CBM

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBMJoel Greenblatt 2014-12-31 Buy 0.01%$16.33 - $24.12
($21.29)
$ 42.9750%New holding78,575
CBMJoel Greenblatt 2013-03-31 Sold Out -0.09%$11.27 - $12.79
($11.93)
$ 42.9772%Sold Out0
CBMJoel Greenblatt 2012-12-31 Buy 0.09%$9.34 - $13.96
($11.38)
$ 42.9774%New holding142,352
CBMJoel Greenblatt 2012-09-30 Sold Out -0.02%$9.01 - $13.01
($11.05)
$ 42.9774%Sold Out0
CBMJoel Greenblatt 2012-06-30 Buy 0.02%$5.96 - $9.16
($7.07)
$ 42.9784%New holding30,208
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBM is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CBM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Magnini AldoManagin Director-Profarmaco 2015-02-12Sell7,500$32.7531.21view
SARGEN GREGORYEVP & CFO 2015-02-12Sell25,000$32.6431.65view
KLOSK STEVEN MPresident & CEO 2015-02-10Sell45,000$30.3241.72view
Haskel William M.Senior Vice President 2014-11-13Sell7,500$2479.04view
Haskel William M.Senior Vice President 2014-11-06Sell15,000$23.3184.34view
Cavanagh ShawnEVP & COO 2014-09-11Sell56,251$22.5690.47view
KLOSK STEVEN MPresident & CEO 2014-09-03Sell126,257$22.0195.23view
Haskel William M.Senior Vice President 2014-09-02Sell9,400$21.9495.85view
KLOSK STEVEN MPresident & CEO 2014-08-19Sell4,702$2295.32view
Haskel William M.Senior Vice President 2014-08-07Sell28,100$22.590.98view

Press Releases about CBM :

    Quarterly/Annual Reports about CBM:

    News about CBM:

    Articles On GuruFocus.com
    Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
    Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
    Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
    Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

    More From Our Partners
    AVEO Upgraded to Strong Buy, Add to Your Portfolio - Analyst Blog Apr 14 2015 - ZACKS

    More From Other Websites
    NYSE stocks posting largest percentage increases Apr 24 2015
    The IBD 50 in an ETF Wrapper Apr 22 2015
    New Innovator IBD 50 ETF Makes Strong Debut - ETF News And Commentary Apr 22 2015
    Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog Apr 13 2015
    5 IBD 50s Offer Triple-Digit Earnings Growth Views Apr 11 2015
    Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015
    Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog Apr 09 2015
    Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog Apr 07 2015
    Cambrex To Present At The 14th Annual Needham Healthcare Conference Apr 07 2015
    Cambrex To Present At The 14th Annual Needham Healthcare Conference Apr 07 2015
    The Medicines Co. Settles Angiomax Patent Dispute with Sun - Analyst Blog Apr 02 2015
    Stock Indexes Post Gains, But Volume Is Light Apr 02 2015
    Stocks Mildly Higher, And CarMax Hits Accelerator Apr 02 2015
    Can Qiagen Continue to Grow in Molecular Diagnostics Space? - Analyst Blog Apr 01 2015
    Will Cambrex (CBM) Continue to Surge Higher? - Tale of the Tape Apr 01 2015
    Cambrex (CBM) Looks Good: Stock Adds 11.6% in Session - Tale of the Tape Apr 01 2015
    Cambrex Surges On Analyst Rating; GrubHub Turns Tail Mar 31 2015
    BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog Mar 31 2015
    Window Dressing Hits Stocks In Final-Hour Sell-Off Mar 31 2015
    Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog Mar 31 2015
    Rally Attempt Stalls; Stocks Trade Lower At Midday Mar 31 2015
    Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog Mar 30 2015
    The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals... Mar 30 2015
    Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog Mar 27 2015
    Cambrex Announces Expansion of Large Scale API Capacity Feb 06 2015
    Cambrex Reports Fourth Quarter And Full Year 2014 Financial Results Feb 06 2015
    Cambrex To Announce Fourth Quarter 2014 Financial Results On February 6, 2015 Feb 04 2015
    Ms. Samantha M. Hanley Promoted To Vice President, General Counsel and Secretary Feb 02 2015
    Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
    Cambrex posts 3Q profit Oct 30 2014
    Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014 Oct 28 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK